New BD Effivax™ Glass Prefillable Syringe

FRANKLIN LAKES, NJ, — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, introduced a next-generation glass prefillable syringe (PFS) that sets a new standard in performance for vaccine PFS with new and tightened specifications for processability, cosmetics, contamination, and integrity.

The new BD Effivax™ Glass Prefillable Syringe has been designed in collaboration with leading pharmaceutical companies to meet the complex and evolving needs of vaccine manufacturing.

“As biopharmaceutical companies continue to rapidly grow their vaccine pipelines, demand for PFS is accelerating across the globe—given their proven ability to facilitate faster administration, support dose sparing and reduce vaccine waste.” said Eric Borin, Worldwide President of BD Pharmaceutical Systems. “The launch of BD Effivax™ Glass Prefillable Syringe strategically supports this growth and will create needed efficiencies in end-to-end production.”

Approximately 70 percent of the top 100 biopharmaceutical companies rely on BD for supply of PFS. BD Effivax™ Glass Prefillable Syringe will further help customers meet the stringent demands of today’s vaccine manufacturing through design enhancements focused on fill/finish and container reliability. Through improved quality specifications, BD BD Effivax™ is designed to reduce the risk of line stoppage and improve the total cost of ownership, manufacturing capacity, and supply availability.